Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Performance - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, administering it at authorized treatment centers (ATCs) [3]. - The company has faced challenges with ATCs, including long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Impact - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - The departure of top-level management at Iovance Therapeutics has raised investor concerns, leading to a nearly 15% decline in the company's stock value during the week [1]. Management Changes - CFO Jean-Marc Bellemin resigned from his position, effective July 10, following a regulatory filing on June 13 [2][4]. - The resignation is occurring during a challenging period for the company, which is facing legal issues and a commercial setback for its flagship drug, Amtagvi [4]. Legal and Commercial Challenges - Iovance is currently under investigation by multiple law firms, which suggests that the company's legal troubles may be contributing to its management instability [2][4]. - The company has experienced a significant reduction in its product-revenue guidance for the year, despite some top-line growth attributed to Amtagvi, a melanoma drug [5]. Investment Outlook - While Iovance is facing significant challenges, Amtagvi still holds potential, indicating that the company may be worth monitoring for investors willing to take on higher risks [6].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2] Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2] - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2] - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4]

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts about the company's growth potential [1]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from May 9, 2024, to May 8, 2025, Iovance provided overly positive statements while concealing significant issues regarding its ability to meet demand for its treatments [1]. - Key factors contributing to the company's poor performance included maintenance that reduced capacity by over 50% for about one month, lower-than-expected Proleukin sales, and a variable pace in the initiation of treatments by approved treatment centers [1]. Financial Impact - Following the announcement of disappointing financial results and lowered revenue guidance on July 25, 2024, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [1]. Next Steps for Shareholders - Shareholders who purchased IOVA shares during the specified class period are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs and receive updates on the case [2]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions that artificially inflated stock prices [3].

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeutic ...

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, administering it at authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were significant delays in patient treatment timelines and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin is resigning to pursue other endeavors, having served since November 2020 [1][2] - The company has not yet named a successor for the CFO position, creating uncertainty during a challenging period [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of full-year revenue projections [3][6] - First-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a securities fraud class-action lawsuit related to its portrayal of authorized treatment centers (ATCs) crucial for Amtagvi's administration [4][5] - The lawsuit alleges discrepancies between the company's claims about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [6][7] - The market's swift reaction reflects investor concerns regarding the company's commercial execution and the accuracy of its operational updates [7]